Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNP-nCOV saRNA-02 in SARS-CoV-2 Seronegative and Seropositive Ugandan Adults
NCT04934111Phase 1Unknown
- Sponsor
- MRC/UVRI and LSHTM Uganda Research Unit
- Start
- Dec 2021
- Primary completion
- Nov 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of LNP-nCOV saRNA-02 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by MRC/UVRI and LSHTM Uganda Research Unit. Primary endpoints: Number of participants with solicited local injection site reactions, Number of participants with solicited systemic reactions and 4 more. Status: unknown.
02
Drugs
LNP-nCOV saRNA-02
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04934111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04934111.